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Abstract 
Purpose: To explore and identify cyclooxygenase (COX) inhibitors with optimal potency and efficacy 
using an arylpropionic acid class of drugs as lead molecules. 
Methods: The selected lead molecules were dimerised through chemical processes (reflux 
condensation) and characterised in terms of structural properties using infrared, proton nuclear 
magnetic resonance, electron impact mass spectrometry, and elemental analysis techniques. The 
molecules were evaluated pharmacologically for acute toxicity and anti-inflammatory (carrageenan-
induced paw oedema test), analgesic (acetic acid-induced writhing test in mice), and antipyretic 
(Brewer’s yeast-induced pyrexia test in mice) activities against control (normal saline) and relevant 
reference standard drugs. Docking analyses were also performed to assess possible protein–ligand 
interactions. 
Results: The test compounds were non-toxic at doses of 50, 100 and 150 mg/kg body weight, ip. 
Pharmacological evaluation revealed that the test compounds, TC-I through TC-IV, had significant anti-
inflammatory and peripheral analgesic activities (p < 0.001). An antipyretic test showed that TC-I, -II, 
and -III showed highly significant antipyretic activities at all doses tested. TC-IV at 20 and 30 mg/kg 
body weight exhibited significant antipyretic activities (p < 0.05), while at 50 mg/kg body weight, the 
activity was highly significant (p < 0.001). Molecular modelling revealed strong inhibitory interactions 
with docking scores of 116.2, 128.8, 144.2, and 136.0 kcal/mol, respectively, in comparison with the 
reference ligand, flurbiprofen (94.9 kcal/mol). 
Conclusion: The dimerised lead drug molecules showed significant anti-inflammatory, analgesic, and 
antipyretic activities in animals and may further be explored as potential new drug candidates for 
inflammatory conditions. 
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Cyclooxygenase (COX) inhibitors, non-steroidal 
anti-inflammatory drugs (NSAIDs), are commonly 
prescribed and used for their anti-inflammatory, 
analgesic, and antipyretic activities. A diverse 
collection of NSAIDs, such as arylpropionic 
acids, arylacetic acids, β­ketoenols, and diary 
heterocycles, acts by inhibiting the activity of 
cyclooxygenase (COX) enzymes [1]. NSAID 
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selection depends on the clinical condition of the 
patient under treatment, COX1 and COX2 
selectivity, duration of use, and gastric ulcerative 
and cardiovascular risks [2]. 
 
A prolific area of research looks at existing drug 
molecules that may be further amplified in terms 
of potency, efficacy, selectivity, or safety. The 
development and successful testing of molecular 
computations for both the receptors (proteins) 
and ligands (drugs) has further aided the efforts 
of researchers, to the point of designing 
appropriate drug structures for both known and 
unknown proteins, receptors, or enzymes [3,4]. 
 
Well-established lead NSAID molecules for 
synthesising derivatives have the advantages of 
predicable pharmacological activities, known 
doses, durations of action, and side and toxic 
effects. The pharmacological evaluation of such 
synthesised analogues, in vivo and through 
computer docking, can provide useful data for 
further augmentation of the existing lead 
molecule; for more benefits and fewer side 
effects, the ‘better’ structure could be screened 
out among the synthesised analogues for further 
optimisation of its pharmacological activity. 
Several success stories have been reported to 
date regarding such computer-aided drug 
discoveries [5]. 
 
Naproxen [6], flurbiprofen [7], and ibuprofen [8], 
belonging to the arylpropionic acid class of non-
selective COX inhibitors, were selected for 
synthesis of their dimers and further exploration 
of these dimers for anti-inflammatory, analgesic, 
and antipyretic activities. Molecular docking 
analyses were also performed to assess 
probable drug-receptor interactions with this new 






Pharmaceutical-grade ibuprofen, flurbiprofen, 
and naproxen were provided by Polyfine 
Chemipharma (Pvt.) Ltd, Hayatabad, Peshawar, 
Pakistan. Ethanol and concentrated sulphuric 
acid were obtained from Sigma-Aldrich, USA. 
Lambda carrageenan (Sigma, USA), glacial 
acetic acid (Panreac, Spain), Brewer’s yeast 
(Merck, Germany), and sterile normal saline I/V 
(Otsoka Japan) were used as received. 
 
The purity of the products was checked on thin-
layer chromatographic plates of aluminium 
coated with silica gel (Kieselgel 60 F25, Merck, 
Germany). Melting points were assessed with a 
Bicot apparatus (Bibby Scientific Ltd., UK). 
Proton nuclear magnetic resonance (1H NMR) 
measurements were performed using a Bruker 
AV 300 system (400 MHz) with dimethyl 
sulphoxide (DMSO) as the solvent. Electron 
impact mass spectroscopy (EI MS) was 
conducted with a JEOL MS Route spectrometer 
(JMS 600-H). Infrared (IR) spectra were obtained 
with a Jasco IR-A-302 spectrometer. Ultraviolet 
(UV) spectra were generated with a Thermo 
Electron Vision Pro (ver. 4.10). C:H:N analyses 
were performed with a Carlo 
ErbaStrumentazione system (Mod-1106, Italy). 
Anti-inflammatory activity tests were conducted 
using a plethysmometer (Model LE 7500 Plan lab 
S.L.). Antinociceptive activity was assessed with 
a hot plate analgesiometer (Harvard Apparatus, 
USA). Antipyretic activity was measured using a 





Ethyl ester analogues of naproxen, flurbiprofen, 
and ibuprofen were synthesised through reflux 
condensation of the reactants in an equimolar 
(0.1 mmol:0.1 mmol) ratio in an acidic 
environment, with the addition of a few drops of 
concentrated sulphuric acid to the reaction [9]. 
Completion of the reaction was monitored using 
thin layer chromatography (TLC), with ethyl 
acetate and hexane as the mobile phase. The 
reaction duration ranged from 12–18 h. The 
resulting solid products were filtered, washed 
with hot hexane (200–400 mL) and distilled water 
(400–500 mL), and then dried (Step 1). Esterified 
compounds thus synthesised were treated with 
hydrazine hydrate, and again subjected to reflux 
condensation for 24–48 h, using ethanol as the 
solvent [10]. Completion of the reactions was 
ascertained using TLC. The products were then 
purified with different techniques (Step 2). The 
esters and hydrazides thus synthesised were 
refluxed overnight, in the presence of 
carbonyldiimidazole (CDI) as the catalyst, using 
acetonitrile as the reaction medium. General 
Scheme I shows dimer formation in a three-step 
reaction. The products formed were then purified 




Mice (BALB-c) from the National Institute of 
Health (NIH) Islamabad, Pakistan, were used for 
the experimental studies. Mice were fed with 
standard food ad libitum with free access to 
drinking water, and kept at 25 ± 2°C with a 12-
h/12-h day/night cycle. The animal studies were 
approved by the Ethical Committee of the 
University of Peshawar, Pakistan (ref no. 01/EC- 
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where = naproxen, flurbiprofen, and ibuprofen. 
 
































15/Pharm), according to international guidelines 
for the handling of animals [11,12]. 
 
Acute toxicity test 
 
For the toxicity study, 18 mice were distributed 
randomly into three groups, n = 6 each. Groups 
were treated with 50, 100, and 500 mg/kg body 
weight of the test compounds intraperitoneally 
(ip) through injection. The animals were 
observed for 6 h for any behavioural changes; 
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mortality rates were determined at 24 h after 
administration of the test compounds [13]. 
 
Anti-inflammatory activity (carrageenan-
induced paw oedema) test 
 
This test was performed on 30 mice distributed 
randomly into five groups, n = 6 each. 
Inflammation was induced by injecting 0.1 mL of 
1% carrageenan solution into the plantar surface 
of the mouse hind paw [14]. Test groups I, II, and 
III were treated with 10, 20, and 30 mg/kg of the 
test compound, respectively. Group IV (control) 
was treated with normal saline (1 mL/kg) while 
group V (reference standard) was treated with 
ketoprofen (10 mg/kg), 30 min before 
carrageenan injection. The paw volume was 
measured at 0, 1, 2, 3, 4, and 5 h using a digital 
plethysmometer. The difference between the 
readings at time 0 h and the different time points 
was taken as the degree of oedema, quantified 
as 
 
% Inhibition = (α – β)/α × 100……………. (1) 
 
where α and β indicate the increase in paw 
volume of control and drug-treated animals, 
respectively. 
 
Evaluation of anti-nociceptive activity 
 
Acetic acid-induced writhing test in mice 
 
Mice were distributed into five groups [groups I, 
II, III, IV (control), and V (reference standard)], n 
= 6 each; at levels of 10, 20, and 30 mg/kg body 
weight ip, doses of the test compounds were 
administered to the animals of the first three 
groups I–III, respectively. The animals of group 
IV received normal saline (10 mL/kg body weight, 
ip) while those of group V were treated with 
diclofenac at a dose of 10 mg/kg body weight, ip. 
After an interval of 30 min after treatment, all 
groups were treated with 0.6% acetic acid at 
10 mL/kg body weight, ip [15]. The mice were 
then placed in individual cages and the numbers 
of writhes were counted for each mouse for a 
period of 30 min, with a 5-min latency period. 
 
Hot plate (thermal) test in mice 
 
Mice weighing 18–22 g of both genders were 
used. As described in a reported protocol, 
animals habituated to the laboratory environment 
for 2 h were distributed into five groups, n = 6 
each. Test groups I, II, and III were treated with 
10, 20, and 30 mg/kg/ip, respectively, of the test 
compound; group IV was treated with normal 
saline (10 mL/kg, ip); and group V with tramadol 
at 5 mg/kg, ip. The animals were subjected to the 
hot plate test after 30- and 60-min intervals; the 
hot plate was maintained at a temperature of 
54.0 ± 0.1°C. The latency time (s), i.e., the 
reaction to the hot plate, was recorded by noting 
the reaction of the experimental animal, licking, 
flicking of the hind limb, or jumping from the 
cylinder [16]. The cut-off time was fixed at 30 s 
for the animal’s reaction to avoid tissue damage 
due to prolonged exposure to the hot plate. Anti-
nociception was determined using the formula: 
 
 …….. (2) 
 
where t is the test latency, c is the control 
latency, and s is the cut-off time. 
 
Anti-pyretic study (Brewer’s yeast-induced 
pyrexia test) 
 
Mice of either sex, weighing 25 – 30 g, were 
used. As described in a reported protocol, before 
the experimental procedure, the animals fasted 
overnight but with free access to water. The 
animals were distributed into five groups, n = 6 
each. Doses of 10, 20, and 30 mg/kg of the test 
compound were administered to the animals of 
the first three groups (groups I–III), respectively. 
Animals of group IV were treated with normal 
saline (10 mL/kg), and those of group V were 
treated with paracetamol (150 mg/kg). Brewer’s 
yeast solution (20 %) was administered 
subcutaneously (sc) below the nape of neck in 
the back of the mice (10 mL/kg body weight) to 
induce hyperpyrexia in the experimental animals 
in all groups [17]. Twenty-four hours after the 
injection, changes in rectal temperature were 
recorded by inserting an oil-lubricated digital 
thermometer into their rectums at 1, 2, 3, 4, and 
5 h. Only those mice whose rectal temperatures 
had increased by at least 0.3–0.5 °C were 




For statistical analyses, GraphPad Prism (ver. 
5.01) software was used. Data pertaining to 
pharmacological evaluation were analysed by 
applying one-way analysis of variance (ANOVA) 
followed by Dunnett’s post hoc analysis. P 
< 0.001 was considered to be highly significant 
while p < 0.05 was considered statistically 
significant in this study. 
 
Molecular docking simulation analysis 
 
AutoDock (ver. 4.0.1.) software was used for 
docking simulation analyses. A rigid-protein-and-
flexible-ligand standard docking procedure was 
performed with the AutoDock Tools, using a 
Lamarckian generic logarithm. A three-
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dimensional 60 × 60 × 60 point grid was built, 
centred on the centre of the M loop of COX2 
(PDB ID: 3PGH). An energy map was calculated 
using a grid spacing of 0.375 Å and a distance-
dependent function of the dielectric constant, 
while default settings were used for the other 
parameters. After completion of the docking, the 
most favourable free binding energies were 
selected as the resulting ligand–protein 
interactions [18]. Flurbiprofen was used as a 
reference and co-crystallised ligand was used to 
assess binding mode accuracy and test 




Chemistry of the synthesised dimers 
 
Test compound (TC)-I: mp = semisolid; yield: 
0.389 g (82.67%): IR (KBr): max 3,527.6, 
3,144.7, 2,826.5, 1,964.4, 1,807.2, 1,624.9, 
1,483.2, 1,414.7, 1,341.4, 1,133.1, 939.3, 914.2, 
769.5, 701.1 cm−1; 1H NMR (400 MHz, 
chloroform): δ 10.08 (s, 1H), 7.77–7.66 (m, 3H), 
7.55–7.38 (m, 7H), 7.36–7.27 (m, J = 12.0 Hz, 
2H), 7.23 (t, J = 1.2, 1.6 Hz 1H), 7.06 (dd, J = 
7.6, 1.6, 1H), 3.81 (s, 3H), 3.52 (m, 2H), 1.34 (d, 
1H), 1.28 (d, 1H). EI MS: m/z (relative 
abundance %): 472 (M+, 5.7), 360 (7.3), 300 
(28.3), 256 (33.2), 220 (100) 156 (60), 136 (30), 
80 (10); elemental analysis for C29H27FN2O3: C, 
72.91; H, 5.28; F, 5.24; N, 7.73; O, 8.83. 
  
Test compound (TC)-II: mp = liquid; yield: 0.28 
g (67.4%): IR (KBr): max 3,160, 2,955, 1,781, 
1,624, 1,512, 1,459, 1,208, 924, 847, 734 cm−1; 
1H NMR (300 MHz, DMSO-d6): δ 12.16 (s, 2H, 
NH), 7.14 (m, 8H, H-2/3/5/6), 4.07 (q, 2H, CH), 
2.39 (d, 4H, CH2), 1.78 (m, 2H, CH), 1.47 (d, 6H, 
CH3), 0.83 (d, 12H, CH3); EI MS: m/z (relative 
abundance %): 246 (50.9), 203 (100), 118 (49.7), 
91 (26.4), 43 (7.5); elemental analysis for 
C26H36N2O2: C, 76.43; H, 8.88; N, 6.86; found: C, 
75.98; H, 8.62; N, 6.90. 
 
Test compound (TC)-III: MP: 77.35°C; yield: 
0.24 g, 53.73%: IR (KBr): max  3,143, 1,770,  
1,604, 1,504, 1,229, 1,031,  960,  820, 745, 719  
cm−1; 1H NMR (300 MHz, DMSO-d6): δ 12.16 (s, 
2H, NH), 7.80 (m, 4H, H-4/8), 7.73 (d, j1,3 = 0.5 
Hz, 2H, H-1), 7.37 (dd, j3, 4 = 8.5 Hz, j3, 1 = 2.0 Hz, 
2H, H-3), 7.30 (d, j5,7 = 2.5 Hz, 2H, H-5), 7.16 
(dd, j7, 8 = 9.0 Hz, j7, 5 = 2.5 Hz, 2H, H-7), 4,25 (q, 
2H, CH), 3.30 (s, 6H, OCH3), 1.56 (d, 6H, CH3); 
EI MS: m/z (relative abundance %): 456 (M+, 
3.4), 438 (58.1), 270 (33.3), 212 (57), 185 (100); 
elemental analysis for C28H28N2O4: C, 73.66; H, 
6.18; N, 6.14; found: C, 73.68; H, 5.17; N, 6.19. 
 
Test compound (TC)-IV: mp: 185.5°C, Yield: 
0.38 g, 79.5%: IR (KBr): max 3,145, 2,826, 1,806, 
1,762, 1,624, 1,483, 1,414, 1,341, 939, 769 cm−1; 
1H NMR (300 MHz, DMSO-d6): δ 11.32 (s, 2H, 
NH), 7.44 (m, 12H, H-5/6/2´/3´/5´/6´), 7.25 (m, 
4H, H-2/4´), 4.23 (q, 2H, CH), 1.53 (d, 6H, CH3); 
EI MS: m/z (relative abundance %): (M+, absent), 
466 (3.9), 284 (100), 269 (63.6), 225 (27.7), 43 
(43.4); elemental analysis for C30H26F2N2O2: C, 
74.36; H, 5.41; N, 5.78; found: C, 74.28; H, 5.82; 




No acute toxicity was observed over the 24 h 
following dosing of 50, 100, or 150 mg/kg body 




Anti-inflammatory activity data were analysed 
using one-way ANOVA followed by Dunnett’s 
post hoc analysis. Figure 1 shows that all test 
compounds had statistically significant anti-
inflammatory effects (*** p < 0.0001) at the given 
doses with reference to normal saline (10 mL/kg) 
as a control and ketoprofen 10 mg/kg as a 
reference standard. Doses of the four 
compounds were selected on the basis of 




The hot plate test was negative for all of the test 
compounds, indicating that the test compounds 
had no central analgesic activity. To avoid a 
congested presentation, data for only the 30 mg 
doses are reported. The overall result of this test 
was negative. 
 
Data for the acetic acid-induced writing test 
indicated that the test compounds (TC-I, -II -III, 
and -IV) were active versus the normal saline 10 
mL/kg control and diclofenac 10 mg/kg reference 
standard (*** p < 0.001), indicating a clear dose–




Brewer’s yeast-induced pyrexia test results 
showed that the antipyretic activity of the four 
compounds was significant (p < 0.001) at all of 
the doses tested versus the control (normal 
saline 10 mL/kg) and paracetamol (150 mg/kg 
body weight) reference standard (Figure 4). 
 
Molecular docking results 
 
Molecular docking simulates and determines the 
best-fit orientation of the ligand (drug) on the  
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Figure 1: Anti-inflammatory activity of TC-I, -II, -III, and –IV, and control (normal saline 10 mL/kg) and reference 
standard (ketoprofen 10 mg/kg). Error bars indicate mean ± SEM (of % inhibition of oedema in the paws of 
experimental animals, n = 6). The anti-inflammatory effects of the test compounds were significant at all three 
doses used (*** p < 0.001) 
 
 
Figure 2: Analgesic sctivity of TC-I, -II, -III, and TC-IV, at 30 mg/kg, and control (normal saline 10 mL/kg) and the 















































































































Figure 3. Summarised comparison showing anti-nociceptive activity of the standard (diclofenac 10 mg/kg) and 
TC-I to IV, and their respective doses (mg/kg) versus the control (normal saline 10 mL/kg). Bars indicate means ± 
SEM of number of writhes in each group (n = 6). The effects were significant for the four compounds 
(*** p < 0.001) 
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Figure 4: Antipyretic activity of the standard (paracetamol 150 mg/kg), test compounds TC-I to IV and 
control (normal saline, 10 mL/kg); mean ± SEM (n = 6). The effects of all four compounds were 
significant (*** p < 0.001) at the respective doses. 
 
basis of binding scores (energies), at the specific 
binding site of the receptor protein, which can 
authenticate or suggest pharmacological activity 
and drug design rationales, with reference to the 
receptor protein studied [20]. COX1, a 
constitutively expressed enzyme, catalyses 
primarily the production of prostaglandins that 
regulate homeostasis, platelet activity, and 
gastric and renal function. COX-2, is a 
constitutive and inducible enzyme that catalyses 
predominantly the production of proinflammatory 
prostaglandins [21]. 
 
Computational modelling tests with the TCs 
revealed that the ‘best’ scoring conformations 
(energies) of the TCs (I, II, III, and IV) were much 
higher than that of flurbiprofen, the reference 
ligand (Table 2, Figures. 5–9). Superimposition 
of the most favourable conformations of the test 
compounds and of the reference ligand 
(Figure 10) showed that they were 
accommodated well within the COX2 active site 
pocket. 
 
Table 2: Highest docking scores of the TCs and 
reference ligand  
 









Figure 5: Docking of flurbiprofen (reference ligand) in 








Figure 7: Docking of TC-II in the active site of the 
COX2 enzyme 
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Figure 10: Superimposition of the most favourable 
conformations of test compounds TC-I (red), TC-II 
(green), TC-III (blue), TC-IV (brownish-orange), and 
the reference ligand, flurbiprofen (yellow), docked in 




Despite remarkable advances in pharmaceutical 
chemistry, inflammatory conditions remain major 
challenges in terms of both curative and 
symptomatic treatments. More effective and 
safer COX inhibitors are required. In our present 
study featuring pharmacological and 
computational analysis, we discovered an 
interesting aspect of COX targeting. What we 
term “dimerised COX inhibitors” are more potent 
than are lead molecules. All test compounds 
exhibited highly significant anti-inflammatory and 
peripheral analgesic activities, and such activities 
were dose-dependent. The effectiveness of an 
NSIAD is related to the rapidity and efficacy of 
access through the narrow COX channel created 
by Arg-120, Tyr-355, and Glu-524 [22]. Our in 
vivo tests clearly showed that COX2 was 
effectively inhibited by dimerised analogues of 
selective lead molecules that were larger in size 
than unitary lead molecules. The active site of 
COX2, which encompasses the Val-523 amino 
acid residue, permits secondary, internal 
hydrophobic extension of the binding site to 
accommodate larger molecules [23]. We suggest 
that this explains the responses to our test 
compounds; this suggestion is supported by our 
molecular docking analysis. The docking scores 
of the test compounds (Table 2), and 
superimposition of the most favourable 
confirmations [24] (Fig. 10), both support this 
hypothesis. Arylpropionic acid COX inhibitors 
bind in one of two reported poses within the COX 
binding pocket: (i) in a way that the carboxylate 
moiety is bound to the edifice site residues Arg-
120 and Tyr-355, such as flurbiprofen [25, 26], or 
(ii) whereby the carboxylate moiety binds to the 
side chains of Tyr-385 and/or Ser-530 residues 
in an upturned fashion, such as diclofenac [20]. 
The ‘best’ conformations of the test compounds 
showed that TC-I was bound via a hydrogen 
bond with Ser-530, TC-II with Try-355, TC-III had 
only hydrophobic interactions (Val-116, Leu-359, 
Leu-351, Leu-354, Val-344, Leu-352, Phe-518, 
Leu-384, Val-523, and Met-522), also reported 
as a ‘second anchoring site’ by Jelena [23]. In 
contrast, TC-IV featured a hydrogen bond 
between Try-385 and Ser-530. Computational 
studies firmly supported the data of the in vivo 
experiments. It appears that the dimerisation 
concept may be used to identify useful lead 
compounds, opening a novel window into the 
management of overwhelming inflammatory 
disorders. These fascinating detailed findings 
warrant further mechanistic studies, with a focus 
on sequential virtual design, chemical 
modification, and 3DQSAR evaluation. 




The in vivo results demonstrate that dimerisation, 
homo- or hetero-, within the selected lead drug 
molecules increased pharmacological activities 
(anti-inflammatory, analgesic and antipyretic). 
Thus, all four dimers should be assessed further 
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